Odinachi Oguh, MD
Neurology · Las Vegas, NVNPI 1376744870
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.5%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 34.5% of the total. Reporting peaked in 2023 at $10,999 and has fallen 94.3% since, to $622 in 2025.
Across 93 payments — averaging $224.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$7K
- Sunovion Pharmaceuticals Inc.$4K
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$2K
- UCB, Inc.$2K
- Boston Scientific$830
- plus $2K from 13 others
Across 23 payments — averaging $5775.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merz Pharmaceuticals, LLC$60K
- AbbVie$43K
- Amylyx Pharmaceuticals, Inc.$23K
- UCB SA$8K
What the payments were for
- Consulting fees$9,70547%
- Speaking & faculty fees$3,87519%
- Travel & lodging$2,27111%
- Food & beverage$4,78223%
- Education$2301%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 10 | $7,208 |
| Sunovion Pharmaceuticals Inc. | 4 | $3,989 |
| AbbVie | 19 | $2,828 |
| Teva Pharmaceuticals USA, Inc. | 9 | $2,476 |
| UCB, Inc. | 6 | $1,616 |
| Boston Scientific | 6 | $830 |
| Merz Pharmaceuticals, LLC | 3 | $397 |
| Acadia Pharmaceuticals Inc | 18 | $319 |
| Abbott | 5 | $281 |
| Medtronic | 1 | $173 |
| Amneal Pharmaceuticals LLC | 4 | $167 |
| Insightec,inc | 1 | $146 |
| Kyowa Kirin, Inc. | 1 | $131 |
| TG Therapeutics, Inc. | 1 | $115 |
| Genentech USA, Inc. | 1 | $91 |
| Sage Therapeutics, LLC | 1 | $34 |
| Revance Therapeutics, Inc. | 1 | $27 |
| MDD US Operations, LLC | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$6,936
- KYNMOBI$3,875
- Austedo XR$2,101
- Duopa$2,100
- VERCISE$681
- XEOMIN$397
- Percept$173
- Exablate$146
- NOURIANZ$131
- BOTOX$125
- INFINITY$117
- BRIUMVI$115
- RYTARY$115
- LONHALA MAGNAIR$114
- Infinity DBS Pulse Generators$107
How this compares
$20,862 in reported general payments places this provider in the 80th percentile of 145 neurology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 234 | $344,710 |
| GocovriAmantadine Hcl | 104 | $340,598 |
| IngrezzaValbenazine Tosylate | 36 | $314,848 |
| AustedoDeutetrabenazine | 23 | $309,281 |
| NuplazidPimavanserin Tartrate | 51 | $299,651 |
| Austedo XrDeutetrabenazine | 17 | $141,719 |
| InbrijaLevodopa | 20 | $69,708 |
| OngentysOpicapone | 16 | $19,363 |
| NeuproRotigotine | 17 | $19,248 |
| Rivastigmine | 96 | $16,653 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 482 | $15,439 |
| AmantadineAmantadine Hcl | 199 | $15,170 |
| Rasagiline Mesylate | 36 | $6,106 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 140 | $4,831 |
| Scopolamine | 14 | $2,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $2,476 | $451,00040 claims |
| Amneal Pharmaceuticals LLCRytary | $167 | $344,710234 claims |
| MDD US Operations, LLCGocovri | $19 | $340,598104 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $7,208 | $334,21152 claims |
| Acadia Pharmaceuticals IncNuplazid | $319 | $299,65151 claims |
| UCB, Inc.Neupro | $1,616 | $19,24817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 145 neurology providers in Nevada.
Other neurology in Las Vegas
- Zoltan MariLas Vegas$629K
- Fan ZhangLas Vegas$398K
- le HuaLas Vegas$385K
- Mehdi AnsariniaLas Vegas$306K
- Carrie HershLas Vegas$209K
- Shanker DixitLas Vegas$137K
- Charles KamenLas Vegas$124K
- Toya MaloneLas Vegas$123K
- Nicole TheuvenetLas Vegas$120K
- Kevin XieLas Vegas$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.